• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

CRIS [ Curis Inc ]
Last Trade 1.07 Date 9/29/2020
Change % 0.95 % Price Change 0.01
Open 1.09 52 Week High 3.59
High 1.12 52 Week Low 0.62
Low 1.04 Type stock
Volume 266856 Average Volume 206349
Prev Close 1.06 Stock Exchange NASDAQ
Bid 1.06 Ask 1.17
Bid Size 50 Ask Size 2
1st Yr Estimated EPS Growth -0.618 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share -0.564 Book Value Yield -0.5271
Buy Back Yield CAPE Ratio
Cash Return -0.5161 Cash Flow per Share -0.7537
Cash Flow Yield -0.7044 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.8318 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income
EV / Revenue 3.7556 EV / Total Asset 0.9367
Expected Dividend Growth Rate Free Cash Flow per Share -0.7679
Free Caash Flow Ratio Free Cash Flow Yield -0.7177
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.3178 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio PB Ratio 10 Year Growth
PB Ratio 3 Year Growth 17.946024 Cash Ratio 3 Year Average 202.435
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 291.259408 PE Ratio 10 Year Growth
PE Ratio 10 Year High 550.0 PE Ratio 10 Year Low 100.666667
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 0.972727
Price to Cash Ratio 2.44004 Price / EBITDA
Price to Sales Ratio 3.349437 Price to Sales Ratio 10 Year Growth -0.063952
Price to Sales Ratio 3 Year Avg 6.755215 Price to Sales Ratio 5 Year Avg
Sale per Share 0.3195 Sales Yield 0.2986
Sustainable Growth Rate Tangible Book Value per Share -0.7307
Tangible Book Value per Share 3 year Avg -0.2155 Tangible Book Value per Share 5 year Avg 0.5949
Total Asset per Share 0.8344 Total Yield
Working Capital per Share 0.3325 Working Capital per Share 3 Year Avg 1.0948
Working Capital per Share 5 Year Avg 1.6466 Beta 2.323447
Company Profile

Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, under collaboration with Genentech, Inc., is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase, epidermal growth factor receptor, and epidermal growth factor receptor 2. In addition, Curis has a development candidate, Debio 0932, which is a Heat Shock Protein 90 or Hsp90 inhibitor. The company holds a license agreement with Debiopharm related to its Hsp90 technologies. Further, it involves in preclinical testing for the development of candidates from its targeted cancer programs. The company was founded in 2000 and is based in Cambridge, Massachusetts.